GlassScriptPhysician profile
Bethany Parsell
NPI 1639561392
$2,366.35
in general payments reported to CMS, 2019-2025
25 companies · $269 in 2025
The $269 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $191 · 2022: $1,244 · 2023: $337 · 2024: $326 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $931.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $931.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,210.09 | 2022-2025 | Interstim |
| Endo Pharmaceuticals INC. | $164.80 | 2021-2023 | Xiaflex, Edex, Aveed |
| Astellas Pharma US INC | $159.76 | 2021-2023 | Myrbetriq |
| Myovant Sciences INC. | $89.94 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $85.91 | 2023-2024 | Orgovyx, Gemtesa |
| Olympus America INC. | $74.40 | 2023-2024 | Itind System |
| Abbvie INC. | $67.17 | 2022-2025 | |
| Urovant Sciences INC | $57.74 | 2021-2022 | |
| Endo USA, INC. | $48.37 | 2024-2025 | Xiaflex, Aveed |
| Sanofi-Aventis U.S. LLC | $45.55 | 2022 | |
| Boston Scientific Corporation | $44.87 | 2022-2023 | Rezum Generator |
| Axonics, INC. | $40.41 | 2022-2024 | Axonics |
| Progenics Pharmaceuticals, INC. | $36.63 | 2025 | |
| Corcept Therapeutics | $27.86 | 2024 | Korlym |
| Coloplast Corp | $27.26 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Telix Pharmaceuticals | $24.80 | 2023 | Illuccix |
| Tolmar, INC. | $24.33 | 2023 | |
| Laborie Medical Technologies Corp. | $20.68 | 2025 | |
| Janssen Pharmaceuticals, INC | $20.38 | 2025 | Spravato |
| Urogen Pharma, INC. | $18.84 | 2025 | |
| Janssen Biotech, INC. | $18.56 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $16.62 | 2023 | Lynparza |
| Verity Pharmaceuticals INC. | $14.85 | 2024 | Trelstar |
| Otsuka America Pharmaceutical, INC. | $14.83 | 2023 | Rexulti |
| Tolmar Pharmaceuticals, INC. | $11.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Parsell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.